Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

0.5994 +0.0094 (+1.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 123,634
Open 0.5900
Bid (Size) 0.5703 (12)
Ask (Size) 0.6000 (9)
Prev. Close 0.5900
Today's Range 0.5642 - 0.6000
52wk Range 0.4500 - 3.470
Shares Outstanding 28,432,275
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023
VBIV stock results show that VBI Vaccines beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
VBI Vaccines Reports Full Year 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire

Performance

YTD
-2.71%
-2.71%
1 Month
+3.34%
+3.34%
3 Month
-5.68%
-5.68%
6 Month
-0.76%
-0.76%
1 Year
-74.82%
-74.82%

More News

Read More
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From VBI Vaccines Inc.
Via Business Wire
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From VBI Vaccines Inc.
Via Business Wire
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
From VBI Vaccines Inc.
Via Business Wire
Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
From VBI Vaccines Inc.
Via Business Wire
Why Faraday Future Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Third Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Second Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.